Patient demographics and disease characteristics at baseline by treatment arm in patients with positive anti-HBc serology (analysis population, n = 326)
| Characteristic . | G-Chemo (n = 155) . | R-Chemo (n = 171) . |
|---|---|---|
| Median age, y (range) | 61 (25-81) | 59 (19-83) |
| Female, n (%) | 60 (38.7) | 81 (47.4) |
| Race, n (%) | ||
| White | 49 (31.6) | 64 (37.4) |
| Black | 3 (1.9) | 0 |
| Asian | 103 (66.5) | 105 (61.4) |
| Other | 0 | 2 (1.2) |
| Region, n (%) | ||
| East Asia* | 86 (55.5) | 89 (52.0) |
| Europe† | 48 (31.0) | 57 (33.3) |
| Other‡ | 21 (13.5) | 25 (14.6) |
| Lymphoma type, n (%) | ||
| DLBCL (GOYA) | 121 (78.1) | 114 (66.7) |
| FL (GALLIUM) | 29 (18.7) | 53 (31.0) |
| MZL (GALLIUM) | 5 (3.2) | 4 (2.3) |
| HBV serology, n (%) | ||
| Anti-HBc+, anti-HBs+ | 94 (60.6) | 113 (66.1) |
| Anti-HBc+, anti-HBs- | 57 (36.8) | 52 (30.4) |
| Missing anti-HBs | 4 (2.6) | 6 (3.5) |
| HBV DNA <29 IU/mL at baseline, n (%) | ||
| Not detectable | 143 (92.3) | 157 (91.8) |
| Detectable, but not quantifiable | 7 (4.5) | 4 (2.3) |
| Missing | 5 (3.2) | 10 (5.8) |
| ECOG performance status, n (%) | ||
| 0 | 76 (49.0) | 81 (47.4) |
| 1 | 68 (43.9) | 69 (40.4) |
| 2 | 11 (7.1) | 21 (12.3) |
| IPI risk category (GOYA), n (%) | n = 121 | n = 114 |
| High | 20 (16.5) | 18 (15.8) |
| High-intermediate | 41 (33.9) | 31 (27.2) |
| Low-intermediate | 38 (31.4) | 42 (36.8) |
| Low | 22 (18.2) | 23 (20.2) |
| FLIPI-1 risk category (GALLIUM, FL), n (%) | n = 29 | n = 53 |
| High | 11 (37.9) | 21 (39.6) |
| Intermediate | 10 (34.5) | 19 (35.8) |
| Low | 8 (27.6) | 13 (24.5) |
| IPI risk category (GALLIUM, non-FL), n (%) | n = 5 | n = 4 |
| High | 1 (20.0) | 0 |
| High-intermediate | 2 (40.0) | 2 (50.0) |
| Low-intermediate | 1 (20.0) | 1 (25.0) |
| Low | 1 (20.0) | 1 (25.0) |
| Prophylactic NAT, n (%) | 40 (25.8) | 54 (31.6) |
| Lamivudine | 33 (21.3) | 46 (26.9) |
| Entecavir | 7 (4.5) | 8 (4.7) |
| Treatment, n (%) | ||
| CHOP | 141 (91.0)§ | 148 (86.5)‖ |
| Benda | 13 (8.4) | 19 (11.1) |
| CVP | 1 (0.6) | 4 (2.3) |
| Characteristic . | G-Chemo (n = 155) . | R-Chemo (n = 171) . |
|---|---|---|
| Median age, y (range) | 61 (25-81) | 59 (19-83) |
| Female, n (%) | 60 (38.7) | 81 (47.4) |
| Race, n (%) | ||
| White | 49 (31.6) | 64 (37.4) |
| Black | 3 (1.9) | 0 |
| Asian | 103 (66.5) | 105 (61.4) |
| Other | 0 | 2 (1.2) |
| Region, n (%) | ||
| East Asia* | 86 (55.5) | 89 (52.0) |
| Europe† | 48 (31.0) | 57 (33.3) |
| Other‡ | 21 (13.5) | 25 (14.6) |
| Lymphoma type, n (%) | ||
| DLBCL (GOYA) | 121 (78.1) | 114 (66.7) |
| FL (GALLIUM) | 29 (18.7) | 53 (31.0) |
| MZL (GALLIUM) | 5 (3.2) | 4 (2.3) |
| HBV serology, n (%) | ||
| Anti-HBc+, anti-HBs+ | 94 (60.6) | 113 (66.1) |
| Anti-HBc+, anti-HBs- | 57 (36.8) | 52 (30.4) |
| Missing anti-HBs | 4 (2.6) | 6 (3.5) |
| HBV DNA <29 IU/mL at baseline, n (%) | ||
| Not detectable | 143 (92.3) | 157 (91.8) |
| Detectable, but not quantifiable | 7 (4.5) | 4 (2.3) |
| Missing | 5 (3.2) | 10 (5.8) |
| ECOG performance status, n (%) | ||
| 0 | 76 (49.0) | 81 (47.4) |
| 1 | 68 (43.9) | 69 (40.4) |
| 2 | 11 (7.1) | 21 (12.3) |
| IPI risk category (GOYA), n (%) | n = 121 | n = 114 |
| High | 20 (16.5) | 18 (15.8) |
| High-intermediate | 41 (33.9) | 31 (27.2) |
| Low-intermediate | 38 (31.4) | 42 (36.8) |
| Low | 22 (18.2) | 23 (20.2) |
| FLIPI-1 risk category (GALLIUM, FL), n (%) | n = 29 | n = 53 |
| High | 11 (37.9) | 21 (39.6) |
| Intermediate | 10 (34.5) | 19 (35.8) |
| Low | 8 (27.6) | 13 (24.5) |
| IPI risk category (GALLIUM, non-FL), n (%) | n = 5 | n = 4 |
| High | 1 (20.0) | 0 |
| High-intermediate | 2 (40.0) | 2 (50.0) |
| Low-intermediate | 1 (20.0) | 1 (25.0) |
| Low | 1 (20.0) | 1 (25.0) |
| Prophylactic NAT, n (%) | 40 (25.8) | 54 (31.6) |
| Lamivudine | 33 (21.3) | 46 (26.9) |
| Entecavir | 7 (4.5) | 8 (4.7) |
| Treatment, n (%) | ||
| CHOP | 141 (91.0)§ | 148 (86.5)‖ |
| Benda | 13 (8.4) | 19 (11.1) |
| CVP | 1 (0.6) | 4 (2.3) |
Benda, bendamustine; Chemo, chemotherapy; CVP, cyclophosphamide, vincristine, and prednisone; ECOG, Eastern Cooperative Oncology Group; FLIPI, Follicular Lymphoma International Prognostic Index; G, obinutuzumab; IPI, International Prognostic Index; MZL, marginal zone lymphoma; R, rituximab.
East Asia includes China, Japan, South Korea, and Taiwan.
Europe includes Belgium, Czech Republic, Germany, Hungary, Italy, Russia, Spain, Switzerland, and the United Kingdom.
Other includes Australia, Canada, and Thailand.
G-CHOP: GOYA, n = 121; GALLIUM, n = 20.
R-CHOP: GOYA, n = 114; GALLIUM, n = 34.